Patents by Inventor Ye CHE

Ye CHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RSV F Protein Mutants
    Publication number: 20190125861
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 2, 2019
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • RSV F protein mutants
    Patent number: 10238732
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 26, 2019
    Assignee: Pfizer Inc.
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF
    Publication number: 20190002466
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: April 19, 2016
    Publication date: January 3, 2019
    Applicant: Pfizer Inc.
    Inventors: Atli THORARENSEN, Matthew Frank BROWN, Agustin CASIMIRO-GARCIA, Ye CHE, Mark Edward FLANAGAN, Adam Matthew GILBERT, Matthew Merrill HAYWARD, Jean-Baptiste TELLIEZ, Rayomand Jal UNWALLA, John I. TRUJILLO, Sidney Xi LIANG
  • RSV F Protein Mutants
    Publication number: 20180177864
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Application
    Filed: February 14, 2018
    Publication date: June 28, 2018
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • RSV F protein mutants
    Patent number: 9950058
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: April 24, 2018
    Assignee: Pfizer Inc.
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES
    Publication number: 20170247372
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: March 1, 2017
    Publication date: August 31, 2017
    Applicant: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • RSV F Protein Mutants
    Publication number: 20170182151
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Application
    Filed: December 20, 2016
    Publication date: June 29, 2017
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
    Patent number: 9617258
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • N-link hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 9180123
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: November 10, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joesph Melnick, Justin Ian Montgomery, Usa Reilly
  • N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents
    Publication number: 20150182513
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Applicant: PFIZER INC.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joesph Melnick, Justin Ian Montgomery, Usa Reilly
  • PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES
    Publication number: 20150158864
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 11, 2015
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla
  • N-link hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 9018384
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: April 28, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joesph Melnick, Justin Ian Montgomery, Usa Reilly
  • N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents
    Publication number: 20140343031
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joesph Melnick, Justin Ian Montgomery, Usa Reilly
  • N-link hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 8846933
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: September 30, 2014
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
  • Fluoro-pyridinone derivatives useful as antibacterial agents
    Patent number: 8779148
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: July 15, 2014
    Assignee: Pfizer Inc.
    Inventors: Usa Reilly, Michael Joseph Melnick, Matthew Frank Brown, Mark Stephen Plummer, Justin Ian Montgomery, Ye Che, Loren Michael Price
  • N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents
    Publication number: 20140128363
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
  • N-linked hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 8664401
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R1, R2, R3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 4, 2014
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
  • FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
    Publication number: 20140057919
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: Pfizer Inc.
    Inventors: Usa Reilly, Michael Joseph Melnick, Matthew Frank Brown, Mark Stephen Plummer, Justin Ian Montgomery, Ye Che, Loren Michael Price
  • Fluoro-pyridinone derivatives useful as antibacterial agents
    Patent number: 8624034
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: January 7, 2014
    Assignee: Pfizer Inc.
    Inventors: Usa Reilly, Michael Melnick, Matthew F. Brown, Mark S. Plummer, Justin Montgomery, Ye Che, Loren Price
  • N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents
    Publication number: 20120258948
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R1, R2, R3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.
    Type: Application
    Filed: December 6, 2010
    Publication date: October 11, 2012
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly